Form 4: Tarsus Pharmaceuticals CEO Bobak R. Azamian Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.
Summary
- Bobak R. Azamian, the President/CEO and Board Chair of Tarsus Pharmaceuticals, filed a Form 4 on March 7, 2025.
- The filing reports the grant of stock options to purchase 90,736 shares of common stock at an exercise price of $44.54 on March 5, 2025.
- These options vest 25% on March 5, 2026, and then 1/48th monthly for the following three years, contingent upon continuous service.
- Azamian also received 59,512 restricted stock units (RSUs) on March 5, 2025.
- These RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to continuous service.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, which are generally viewed favorably as they align management's interests with shareholders.
Positives
- The grant of stock options and RSUs to the CEO aligns his interests with those of the shareholders.
- The vesting schedules incentivize long-term performance and retention.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.
Industry Context
Granting stock options and RSUs is a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. The vesting schedules are typical for executive compensation packages.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation practices for CEOs in publicly traded companies, particularly in the pharmaceutical sector.
- Vesting schedules of three to four years are also typical to ensure long-term commitment.
- Comparable companies like Alcon or Bausch + Lomb also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- Shareholders may view the equity grants positively as they incentivize the CEO to increase shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date of stock option and RSU grants |
| 03/05/2026 | Initial vesting date for 25% of stock options |
| 03/15/2026 | First annual vesting date for RSUs |
| 03/15/2027 | Second annual vesting date for RSUs |
| 03/15/2028 | Third annual vesting date for RSUs |
| 03/15/2029 | Final annual vesting date for RSUs |
| 03/04/2035 | Expiration date for stock options |
| 03/07/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.